echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Kelun RET inhibitor reaches overseas authorization

    Kelun RET inhibitor reaches overseas authorization

    • Last Update: 2021-05-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 25, Kelun Pharmaceutical issued an announcement stating that its subsidiary Kelun Botai had reached a regional authorization cooperation agreement with Ellipses Pharma LTD in the United Kingdom.


    A400 R & D project is the Cologne Great proprietary small molecule selective targeting RET kinase inhibitor formulation, the project was completed in March 2021 formally submitted an IND to the NMPA, layout and has a number of international patents.


    Preparation, the project has formally submitted an IND application to NMPA in March 2021, and has laid out a number of international patents.
    Preclinical studies have shown that a good in vivo A400 kinase inhibitory activity and selectivity; animal blood / brain bursts having advantages in the amount of dew and the like; a variety of clinical resistance mutations have been reported clinically effective.
    A400 has the potential to overcome clinical drug-resistant mutations and improve the clinical efficacy of brain metastases.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.